@article{31bb06f6ee14414681670ced108a95c6,
title = "Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease",
abstract = "Objective: We compared the ability of arterial spin labeling (ASL), an MRI method that measures cerebral blood flow (CBF), to that of FDG-PET in distinguishing patients with Alzheimer disease (AD) from healthy, age-matched controls. Methods: Fifteen patients with AD (mean age 72 ± 6 years, Mini-Mental State Examination score [MMSE] 20 ± 6) and 19 age-matched controls (mean age 68 ± 6 years, MMSE 29 ± 1) underwent structural MRI. Participants were injected with 5 mCi of FDG during pseudocontinuous ASL scan, which was followed by PET scanning. Statistical parametric mapping and regions of interest (ROI) analysis were used to compare the ability of the 2 modalities in distinguishing patients from controls. Similarity between the 2 modalities was further assessed with linear correlation maps of CBF and metabolism to neuropsychological test scores. Results: Good agreement between hypoperfusion and hypometabolism patterns was observed, with overlap primarily in bilateral angular gyri and posterior cingulate. ROI results showed similar scales of functional deficit between patients and controls in both modalities. Both ASL and FDGPET were able to distinguish neural networks associated with different neuropsychological tests with good overlap between modalities. Conclusions: Our voxel-wise results indicated that ASL-MRI provides largely overlapping information with FDG-PET. ROI analysis demonstrated that both modalities detected similar degrees of functional deficits in affected areas. Given its ease of acquisition and noninvasiveness, ASL-MRI may be an appealing alternative for AD studies.",
author = "Y. Chen and Wolk, {D. A.} and Reddin, {J. S.} and M. Korczykowski and Martinez, {P. M.} and Musiek, {E. S.} and Newberg, {A. B.} and P. Julin and Arnold, {S. E.} and Greenberg, {J. H.} and Detre, {John A.}",
note = "Funding Information: Dr. Chen reports no disclosures. Dr. Wolk serves as a consultant for GE Healthcare; and receives/has received research support from GE Healthcare, Pfizer Inc, the NIH, and the PA Department of Health. Dr. Reddin has received funding for travel and speaker honoraria from Janssen. M. Korczykowski, P.M. Martinez, and Dr. Musiek report no disclosures. Dr. Newberg receives research support from the NIH. Dr. Julin is a full-time employee of AstraZeneca. Dr. Arnold serves on a scientific advisory board for Eli Lilly and Company; serves on the editorial boards of Translational Neuroscience and Schizophrenia Bulletin ; serves as a consultant for the Cowen Group; and receives research support from Eli Lilly and Company, Pfizer Inc, Janssen, Neuronetrix, Johnson & Johnson, the NIH, and the Marian S. Ware Family Foundation. Dr. Greenberg serves on the editorial board of the Journal of Cerebral Blood Flow and Metabolism ; has a patent pending re: Use of diffuse correlation spectroscopy for the non-invasive measurement of cerebral blood flow; and receives research support from the NIH/NINDS and the Institute for Translational Medicine and Therapeutics (University of Pennsylvania). Dr. Detre serves on a scientific advisory board of Pittsburgh NMR Center; serves as an Associate Editor of the Journal of Neuroimaging ; serves as a consultant for Pfizer Inc; receives research support from Wyeth, AstraZeneca, Pfizer Inc, the National Science Foundation, and the NIH; is an inventor on a patent re: ASL perfusion MRI and receives royalties from the University of Pennsylvania for its licensure; and has acted as a witness or consultant in legal proceedings.",
year = "2011",
month = nov,
day = "29",
doi = "10.1212/WNL.0b013e31823a0ef7",
language = "English",
volume = "77",
pages = "1977--1985",
journal = "Neurology",
issn = "0028-3878",
number = "22",
}